CohBar (CWBR) Prices 20.83M Share Offering at $0.72/sh
- Wall Street opens higher after virus-driven rout
- Private sector employment increased by 534,000 jobs from October to November, topping consensus estimate
- Jim Paulsen Sees Correction Exceeding 10%, Sees Cyclicals, Small and Mid Caps Outperforming Large Caps and Tech
- Apple (AAPL) iPhone 13 Lead Times Easing as Supply Chain Improves - UBS
- Salesforce (CRM) Shares Plunge on Weaker Profit Guidance, Bull Thesis Remains Intact Says Analyst
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the pricing of an underwritten public offering of 20,833,334 shares of the Company’s common stock and accompanying warrants to purchase 20,833,334 shares of common stock at a price to the public of $0.72 per share and accompanying warrant. Each warrant will have an exercise price of $0.72 per share and be exercisable for 5 years from the closing date of the offering. The aggregate gross proceeds from this offering are expected to be approximately $15.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The offering is expected to close on or about November 1, 2021, subject to customary closing conditions.
Cantor Fitzgerald & Co. is acting as sole book-running manager for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, is acting as co-manager.
CohBar intends to use the net proceeds from the offering, together with its existing cash resources, for general corporate purposes, which may include funding preclinical and clinical development of its peptides, increasing working capital, operating expenses and capital expenditures.
The securities will be issued pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (SEC) on August 24, 2020. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC’s website at www.sec.gov or from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Ave., 4th Floor, New York, New York 10022, or by e-mail at firstname.lastname@example.org.
This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Qualigen Therapeutics (QLGN) Announces $8.82M Registered Direct Common Stock Offering
- Longeveron (LGVN) Prices 1.17M Share Offering $17.50/sh
- Huize Holding Limited (HUIZ) Reports Q3 Revenue of $48.9M, Adjusted Net Loss of $13.4M, Revises FY Guidance Upward
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Related EntitiesCantor Fitzgerald
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!